According to a new report published by Introspective Market Research, titled, Complete Blood Count Device Market by Device Type, End-User, Technology, and Region, The Global Complete Blood Count Device Market Size Was Valued at USD 4.2 Billion in 2023 and is Projected to Reach USD 8.7 Billion by 2032, Growing at a CAGR of 8.3%. The Global Complete Blood Count (CBC) Device Market is poised for substantial growth as demand for rapid, accurate hematology diagnostics increases in clinical and research settings. CBC devices are used to measure vital blood components such as red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. Compared to manual methods, modern CBC analyzers deliver higher throughput, better precision, and automated workflows, reducing human error and turnaround time.
These devices find application in hospitals, diagnostic labs, blood banks, and research institutes. With the rising prevalence of chronic diseases, infections, and hematological disorders, routine blood testing is becoming indispensable. Moreover, advances in microfluidics, AI algorithms for hematology, and point-of-care integration are pushing the capabilities of CBC devices ahead of conventional benchtop instruments.
The Complete Blood Count Device Market is segmented into Device Type, End-User, and Technology. By Device Type, the market is categorized into (Automated Analyzers, Semi-Automated Analyzers, Point-of-Care Devices). By End-User, the market is categorized into (Hospitals, Diagnostic Laboratories, Research Institutes). By Technology, the market is categorized into (Impedance Technology, Flow Cytometry, Optical/Light Scattering).
The primary growth driver in the Complete Blood Count Device Market is the escalating need for rapid and high-throughput blood diagnostics. As healthcare systems worldwide focus on preventive care and early disease detection, regular blood counts are increasingly prescribed. This demand is further fueled by rising incidence of chronic conditions such as anemia, infections, and cancer. Hospitals and diagnostic laboratories are upgrading legacy systems to advanced CBC devices to improve accuracy, reduce test turnaround time, and manage greater patient loads—thus driving investments in new equipment and enhancing market growth.
A major opportunity lies in the expansion of point-of-care and portable CBC devices for decentralized testing. In remote or resource-constrained regions, having compact, user-friendly CBC analyzers can dramatically improve access to diagnostics. Integration with digital health platforms and telemedicine offers remote result sharing, enabling clinicians in underserved areas to monitor patient health. Leveraging miniaturization, low power design, and cartridge-based consumables, manufacturers can tap into new markets and broaden the adoption of CBC devices beyond traditional labs into clinics, primary care centers, and home settings.
Complete Blood Count Device Market, Segmentation
The Complete Blood Count Device Market is segmented on the basis of Device Type, End-User, and Technology.
Device Type
The Device Type segment is further classified into Automated Analyzers, Semi-Automated Analyzers, and Point-of-Care Devices. Among these, the Automated Analyzers sub-segment accounted for the highest market share in 2024. These systems deliver high throughput, minimal operator intervention, multi-parameter analysis, and reliability in large hospital laboratories. They are preferred for handling high test volumes, integration with laboratory information systems, and enabling continuous operation with minimal downtime.
End-User
The End-User segment is further classified into Hospitals, Diagnostic Laboratories, and Research Institutes. Among these, the Hospitals sub-segment accounted for the highest market share in 2024. Hospitals conduct the bulk of CBC tests as part of routine patient diagnosis, inpatient monitoring, and emergency care workflows. Their scale, budget, and demand for reliable, fast diagnostics make them the primary buyers of advanced CBC devices, driving large purchases of automated analyzers for integrated pathology labs.
Some of The Leading/Active Market Players Are-
- Abbott Laboratories (USA)
- Sysmex Corporation (Japan)
- Beckman Coulter, Inc. (USA)
- Siemens Healthineers (Germany)
- HORIBA Ltd. (Japan)
- Mindray Medical International (China)
- Nihon Kohden Corporation (Japan)
- Roche Diagnostics (Switzerland)
- HemoCue AB (Sweden)
- EKF Diagnostics (UK)
- other active players.
Key Industry Developments
-
In April 2025, Sysmex Corporation launched an AI-enhanced CBC analyzer with advanced anomaly detection features.
Sysmex introduced its new hematology analyzer equipped with machine learning algorithms that can flag abnormal blood cell counts, classify immature cell types, and reduce manual review rates. The system also supports seamless integration with hospital information systems and remote monitoring dashboards. By reducing false positives and streamlining workflow, this innovation aims to improve diagnostic accuracy and operational efficiency, particularly in high-volume clinical settings. - In November 2024, Roche Diagnostics announced an expansion of its CBC reagent manufacturing facility in Europe.
Roche’s expansion aims to increase production capacity for reagents and consumables used in CBC analyzers, ensuring stability of supply amid rising global demand. The upgraded facility incorporates sustainable manufacturing practices, automation, and quality controls. This development secures Roche’s supply chain and supports customers globally in managing reagent shortages and cost pressures, reinforcing their presence in the hematology diagnostics market.
Key Findings of the Study
- Automated analyzers dominate due to high throughput and reliability.
- Hospitals are the largest end-user segment given their diagnostic volume.
- Point-of-care CBC devices present a growth opportunity in decentralized settings.
- AI and integration capabilities are shaping next-gen device innovation.
- Reagent & consumable supply chain stability is key for market expansion.
